PT1326630E - Utilização de péptidos glp-2 - Google Patents

Utilização de péptidos glp-2 Download PDF

Info

Publication number: PT1326630E
Authority: PT; Portugal
Prior art keywords: glp; peptides; hyperparathyroidism; glucagon; analogues
Prior art date: 2000-09-18

Application number

PT01982302T

Other languages

English (en)

Inventor

Dennis Bang Henriksen

Jens Juul Holst

Original Assignee

Sanos Bioscience As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-18

Filing date

2001-09-17

Publication date

2008-09-02

2000-09-18 Priority claimed from GB0022844A external-priority patent/GB0022844D0/en

2000-12-07 Priority claimed from GB0029920A external-priority patent/GB0029920D0/en

2001-09-17 Application filed by Sanos Bioscience As filed Critical Sanos Bioscience As

2008-09-02 Publication of PT1326630E publication Critical patent/PT1326630E/pt

Links

102000004196 processed proteins & peptides Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1
101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 1
201000002980 Hyperparathyroidism Diseases 0.000 abstract 1
102100040918 Pro-glucagon Human genes 0.000 abstract 1
TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Nutrition Science (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Child & Adolescent Psychology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

PT01982302T 2000-09-18 2001-09-17 Utilização de péptidos glp-2 PT1326630E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB0022844A GB0022844D0 (en)	2000-09-18	2000-09-18	Use of GLP-1 and GLP-2 peptides
GB0029920A GB0029920D0 (en)	2000-12-07	2000-12-07	Use of glp-1 and glp-2 peptides

Publications (1)

Publication Number	Publication Date
PT1326630E true PT1326630E (pt)	2008-09-02

Family

ID=26245018

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT01982302T PT1326630E (pt)	2000-09-18	2001-09-17	Utilização de péptidos glp-2
PT01967517T PT1414486E (pt)	2000-09-18	2001-09-18	Utilizaão de glp-2 em combinaão com outro agente teraputico em perturbaães ësseas

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT01967517T PT1414486E (pt)	2000-09-18	2001-09-18	Utilizaão de glp-2 em combinaão com outro agente teraputico em perturbaães ësseas

Country Status (11)

Country	Link
US (2)	US6770620B2 (pt)
EP (3)	EP1326630B1 (pt)
JP (2)	JP5161412B2 (pt)
AT (2)	ATE396738T1 (pt)
AU (2)	AU2002213925A1 (pt)
CY (2)	CY1108263T1 (pt)
DE (2)	DE60134251D1 (pt)
DK (2)	DK1326630T3 (pt)
ES (2)	ES2310192T3 (pt)
PT (2)	PT1326630E (pt)
WO (2)	WO2002022151A2 (pt)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20080249016A1 (en) *	2000-09-18	2008-10-09	Sanos Bioscience A/S	Use of GLP-2 in a combination treatment for bone-related disorders
PT1326630E (pt) *	2000-09-18	2008-09-02	Sanos Bioscience As	Utilização de péptidos glp-2
US7371721B2 (en) *	2000-09-18	2008-05-13	Sanos Bioscience A/S	Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7186683B2 (en) *	2000-09-18	2007-03-06	Sanos Bioscience A/S	Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US20070135345A1 (en) *	2000-09-18	2007-06-14	Henriksen Dennis B	Use of GLP-2 for the treatment or prevention, of bone-related disorders
RO120121B1 (ro) *	2000-12-18	2005-09-30	Elena Ionaşcu	Soluţie injectabilă, cu efect antiinflamator, procedeu de obţinere şi metodă de tratament a bolilor autoimune
CA2347330C (en) *	2001-05-10	2002-03-12	Pharmaceutical Partners Of Canada Inc.	Liquid injectable formulation of disodium pamidronate
DE10135315A1 (de) *	2001-07-19	2003-01-30	Bayer Ag	Stents
CA2471363C (en)	2001-12-21	2014-02-11	Human Genome Sciences, Inc.	Albumin fusion proteins
KR20110043664A (ko) *	2002-05-17	2011-04-27	듀크 유니버시티	비만치료방법
US20050215552A1 (en) *	2002-05-17	2005-09-29	Gadde Kishore M	Method for treating obesity
US7812120B2 (en)	2003-03-21	2010-10-12	Par Pharmaceutical, Inc.	Nasal calcitonin formulations containing chlorobutanol
JP2007525425A (ja) *	2003-03-24	2007-09-06	ノボ　ノルディスク　アクティーゼルスカブ	Ｇｌｐ−２誘導体
EP2316456B1 (en)	2003-04-29	2017-06-14	Orexigen Therapeutics, Inc.	Compositions for affecting weight loss comprising an opioid antagonist and bupropion
EP1870096A3 (en) *	2003-04-29	2011-04-20	Orexigen Therapeutics, Inc.	Compositions for affecting weight loss
CN102174102A (zh)	2003-05-15	2011-09-07	塔夫茨大学信托人	肽和多肽药物的稳定类似物
JP2007517901A (ja) *	2004-01-13	2007-07-05	デューク・ユニバーシティー	体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
US7713959B2 (en) *	2004-01-13	2010-05-11	Duke University	Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20050277579A1 (en) *	2004-05-03	2005-12-15	Ranga Krishnan	Compositions for affecting weight loss
NZ562943A (en) *	2005-05-04	2011-03-31	Zealand Pharma As	Glucagon-like-peptide-2 (glp-2) analogues
WO2006135660A2 (en) *	2005-06-10	2006-12-21	University Of Chicago	Therapies involving lymphotoxin beta receptor
PT2135603E (pt) *	2005-11-22	2013-04-03	Orexigen Therapeutics Inc	Composições e métodos para aumentar a sensibilidade à insulina
WO2007089318A2 (en) *	2005-11-23	2007-08-09	Orexigen Therapeutics, Inc.	Compositions and methods for reducing food cravings
WO2007133747A2 (en) *	2006-05-15	2007-11-22	Wisconsin Alumni Research Foundation	PULMONARY DELIVERY OF 1α,25-DIHYDROXYVITAMIN D3 AND CO-ADMINISTRATION OF PARATHYROID HORMONE OR CALCITONIN
US8916195B2 (en) *	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
NZ597554A (en)	2006-11-08	2014-04-30	Zealand Pharma As	Selective glucagon-like-peptide-2 (glp-2) analogues
AU2007319472B2 (en)	2006-11-09	2013-01-17	Nalpropion Pharmaceuticals Llc	Methods Of Administering Weight Loss Medications
KR101479324B1 (ko)	2006-11-09	2015-01-05	오렉시젠 세러퓨틱스 인크.	신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
EP2124907B1 (en)	2007-03-19	2018-05-30	Vita Sciences, Llc	Transdermal patch and method for delivery of vitamin b12
WO2009033791A2 (en) *	2007-09-11	2009-03-19	Mondobiotech Laboratories Ag	Use of a peptide as a therapeutic agent
EP2303025A4 (en)	2008-05-30	2012-07-04	Orexigen Therapeutics Inc	METHOD FOR TREATING DIGITAL FAT SWITCHES
EP2337585A1 (en) *	2008-09-19	2011-06-29	Nektar Therapeutics	Polymer conjugates of glp-2-like peptides
US20110166063A1 (en)	2008-09-19	2011-07-07	Nektar Therapeutics	Polymer conjugates of therapeutic peptides
KR101820024B1 (ko)	2008-10-17	2018-01-18	사노피-아벤티스 도이칠란트 게엠베하	인슐린과 ｇｌｐ－1 효능제의 병용물
EA201290158A1 (ru) *	2009-09-23	2012-08-30	Биокиер, Инк.	Композиция и способ лечения диабета
EP2311486A1 (en) *	2009-10-07	2011-04-20	Nestec S.A.	GLP-2 for use in intestine and muscle recovery
LT2498801T (lt)	2009-11-13	2018-05-10	Sanofi-Aventis Deutschland Gmbh	Farmacinė kompozicija, apimanti despro36eksendin-4(1-39)-lys6-nh2 ir metioniną
PL3417871T3 (pl)	2009-11-13	2021-06-14	Sanofi-Aventis Deutschland Gmbh	Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę
US9248123B2 (en)	2010-01-11	2016-02-02	Orexigen Therapeutics, Inc.	Methods of providing weight loss therapy in patients with major depression
AU2011202239C1 (en)	2010-05-19	2017-03-16	Sanofi	Long-acting formulations of insulins
MX339614B (es)	2010-08-30	2016-06-02	Sanofi - Aventis Deutschland GmbH	Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2714089A4 (en) *	2011-05-24	2014-11-26	Polyvalor Sec	COMPOSITIONS AND METHODS FOR EFFICIENT AND SAFE DELIVERY OF RNsIS USING SPECIFIC NANOCOMPLEXES BASED ON CHITOSAN
PL2750699T3 (pl)	2011-08-29	2015-12-31	Sanofi Aventis Deutschland	Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
BR112014027345A2 (pt)	2012-05-03	2019-09-03	Zealand Pharma As	análogos de peptídeo 2 semelhante ao glucagon (glp-2)
KR20200035501A (ko)	2012-06-06	2020-04-03	오렉시젠 세러퓨틱스 인크.	과체중 및 비만의 치료 방법
CN110354255B (zh)	2013-04-03	2024-05-14	赛诺菲	通过长效胰岛素制剂治疗糖尿病
CN105637363B (zh)	2013-08-01	2017-06-27	庆熙大学校产学协力团	预防或治疗糖尿病的药物组合物，预防或治疗糖尿病的方法，以及筛选糖尿病治疗药物的方法
WO2015016682A1 (ko) *	2013-08-01	2015-02-05	경희대학교 산학협력단	당뇨병 예방 또는 치료용 약학적 조성물, 당뇨병 예방 또는 치료 방법, 및 당뇨병 치료제 스크리닝 방법
US8969371B1 (en)	2013-12-06	2015-03-03	Orexigen Therapeutics, Inc.	Compositions and methods for weight loss in at risk patient populations
CA2970200A1 (en)	2014-12-12	2016-06-16	Sanofi-Aventis Deutschland Gmbh	Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
WO2016205701A1 (en)	2015-06-19	2016-12-22	University Of Southern California	Enteral fast access tract platform system
WO2016205754A1 (en)	2015-06-19	2016-12-22	University Of Southern California	Compositions and methods for modified nutrient delivery
WO2018009778A1 (en) *	2016-07-07	2018-01-11	Baylor College Of Medicine	Combination of glp-1 and glp-2 for treating or preventing metabolic diseases, disorders and syndromes
WO2018069442A1 (en)	2016-10-12	2018-04-19	University Of Copenhagen	Peptide dual agonists of gipr and glp2r
JP6563614B1 (ja)	2016-12-09	2019-08-21	ジーランド・ファーマ・ア／エス	アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト
EP3694537A1 (en)	2017-10-12	2020-08-19	University of Copenhagen	Combination therapy for treatment of bone disorders
EP3699187A1 (en)	2019-02-21	2020-08-26	Universite D'angers	Peptide targeting gip and glp-2 receptors for treating bone disorders
US20210187077A1 (en) *	2019-12-23	2021-06-24	Idaho State University	GLP-1 Agonist Conjugates for Sustained Glycemic Control
WO2021133087A1 (ko) *	2019-12-24	2021-07-01	한미약품 주식회사	Glp-2 또는 이의 결합체를 포함하는 골 대사성 질환에 대한 예방 또는 치료용 약학적 조성물
KR20220041765A (ko) *	2020-09-25	2022-04-01	한미약품 주식회사	글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 골 질환에 대한 예방 또는 치료용 약학적 조성물

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1498425A1 (en)	1986-05-05	2005-01-19	The General Hospital Corporation	Use of glucagone-like-peptide 1 (GLP-1) derivatives for the preparation of pharmaceutical compositions
WO1990011296A1 (en)	1989-03-20	1990-10-04	The General Hospital Corporation	Insulinotropic hormone
DK0512042T3 (da)	1990-01-24	1998-05-11	Douglas I Buckley	GLP-1-analoger anvendelige ved diabetesbehandling
NZ245015A (en)	1991-11-05	1995-12-21	Transkaryotic Therapies Inc	Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5512459A (en)	1993-07-20	1996-04-30	Bionebraska, Inc.	Enzymatic method for modification or recombinant polypeptides
US6184201B1 (en)	1995-04-14	2001-02-06	Nps Allelix Corp.	Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en)	1995-04-14	1998-11-10	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
US5789379A (en)	1995-04-14	1998-08-04	Allelix Biopharmaceutical Inc.	Glucagon-like peptide-2 analogs
US5990077A (en) *	1995-04-14	1999-11-23	1149336 Ontario Inc.	Glucagon-like peptide-2 and its therapeutic use
BR9707807A (pt)	1996-03-01	1999-07-27	Novo Nordisk As	Uso de uma composição farmacêutica composição farmacêutica processo de tratar doenças ou distúrbios associados com a regulação do apetite prejudicado e uso de um peptideo
US5912229A (en)	1996-03-01	1999-06-15	Novo Nordisk Als	Use of a pharmaceutical composition comprising an appetite-suppressing peptide
DE69716905T2 (de)	1996-04-12	2003-07-24	1149336 Ontario Inc., Toronto	Analoge des glucagon ähnlichen peptides -2
DK0909312T3 (da)	1996-07-05	2003-03-17	Novo Nordisk As	Fremgangsmåde til fremstilling af polypeptider
US5994500A (en)	1996-07-19	1999-11-30	1149336 Ontario Inc.	Antagonists of intestinotrophic GLP-2 peptides
JP2000517308A (ja)	1996-08-30	2000-12-26	ノボノルディスクアクティーゼルスカブ	Ｇｌｐ―２誘導体
US6011155A (en) *	1996-11-07	2000-01-04	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
CA2272854C (en)	1996-12-06	2004-02-10	Amgen Inc.	Keratinocyte growth factors and their use in combination with glucagon-like peptide derivatives
US5952301A (en)	1996-12-10	1999-09-14	1149336 Ontario Inc.	Compositions and methods for enhancing intestinal function
US6077949A (en)	1996-12-13	2000-06-20	Allelix Biopharmaceuticals, Inc.	Cloned glucagon-like peptide 2 receptors
JP4106094B2 (ja)	1996-12-13	2008-06-25	エヌピーエスアレリックスコーポレーション	クローン化グルカゴン様ペプチド２受容体
US6051557A (en)	1997-05-16	2000-04-18	1149336 Ontario Inc.	Methods of enhancing functioning of the upper gastrointestinal tract
DK0981362T3 (da) *	1997-05-16	2004-03-15	Ontario Inc 1149336	Anvendelse af GLP-2-agonister, der forbedrer funktionen af den øvre mavetarmkanal
AU8671798A (en)	1997-07-30	1999-02-22	Betagene, Inc.	Methods and compositions relating to no-mediated cytotoxicity
ES2222613T3 (es)	1997-09-12	2005-02-01	Pharis Biotec Gmbh	Composicion para la terapia de diabetes mellitus y de la obesidad.
AU2149899A (en)	1998-01-23	1999-08-09	Novo Nordisk A/S	Process for making desired polypeptides in yeast
WO1999038501A2 (en)	1998-02-02	1999-08-05	Trustees Of Tufts College	Method of regulating glucose metabolism, and reagents related thereto
AU2712899A (en)	1998-02-27	1999-09-15	Novo Nordisk A/S	Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates
IL138214A0 (en)	1998-03-09	2001-10-31	Zealand Pharmaceuticals As	Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
FR2777283B1 (fr) *	1998-04-10	2000-11-24	Adir	Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU7421598A (en)	1998-05-11	1999-11-29	1149336 Ontario Inc.	Methods of enhancing functioning of the large intestine
CA2339537A1 (en)	1998-08-21	2000-03-02	Barbara Wallner	Regulation of substrate activity
US6193997B1 (en)	1998-09-27	2001-02-27	Generex Pharmaceuticals Inc.	Proteinic drug delivery system using membrane mimetics
JP2002526554A (ja)	1998-10-07	2002-08-20	メディカルカレッジオブジョージアリサーチインスティチュート，インコーポレイテッド	骨親和性ホルモンとして用いられるグルコース依存性インスリン親和性ペプチド
WO2000028982A2 (en) *	1998-11-19	2000-05-25	The Board Of Trustees For The University Of Arkansas	Increasing bone strength with selected bisphosphonates
PL393611A1 (pl) *	1998-12-07	2011-05-09	Societe De Conseils De Recherches Et D'applications Scientifiques Sas	Związki stanowiące analogi GLP-1, kompozycje zawierające takie związki oraz zastosowanie takich związków
EP2322545A1 (en)	1998-12-07	2011-05-18	Ipsen Pharma	Analogues of GLP-1
CO5150173A1 (es)	1998-12-10	2002-04-29	Novartis Ag	Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6271200B1 (en)	1998-12-21	2001-08-07	Generex Pharmaceuticals Inc.	Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
AU3033500A (en)	1999-01-15	2000-08-01	Agouron Pharmaceuticals, Inc.	Non-peptide glp-1 agonists
GB9905416D0 (en)	1999-03-09	1999-05-05	Allelix Biopharma	Small molecules having GLP-2 like activity
US6110949A (en) *	1999-06-24	2000-08-29	Novartis Ag	N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
EP1076066A1 (en)	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
AU2020501A (en)	1999-12-08	2001-06-18	1149336 Ontario Inc.	Chemotherapy treatment
WO2001087322A2 (en) *	2000-05-17	2001-11-22	Bionebraska, Inc.	Peptide pharmaceutical formulations
ATE346093T1 (de) *	2000-06-16	2006-12-15	Lilly Co Eli	Analoge des glucagon ähnlichen peptid-1
CA2417100A1 (en) *	2000-08-02	2002-02-07	Theratechnologies Inc.	Modified peptides with increased potency
PT1326630E (pt)	2000-09-18	2008-09-02	Sanos Bioscience As	Utilização de péptidos glp-2
WO2002066062A2 (en) *	2001-02-01	2002-08-29	Drucker Daniel J	Enhancement of glp-2 activity

2001
- 2001-09-17 PT PT01982302T patent/PT1326630E/pt unknown
- 2001-09-17 WO PCT/EP2001/010714 patent/WO2002022151A2/en active IP Right Grant
- 2001-09-17 EP EP01982302A patent/EP1326630B1/en not_active Expired - Lifetime
- 2001-09-17 AU AU2002213925A patent/AU2002213925A1/en not_active Abandoned
- 2001-09-17 DK DK01982302T patent/DK1326630T3/da active
- 2001-09-17 EP EP08156283A patent/EP1970072A1/en not_active Withdrawn
- 2001-09-17 JP JP2002526401A patent/JP5161412B2/ja not_active Expired - Fee Related
- 2001-09-17 AT AT01982302T patent/ATE396738T1/de active
- 2001-09-17 DE DE60134251T patent/DE60134251D1/de not_active Expired - Lifetime
- 2001-09-17 ES ES01982302T patent/ES2310192T3/es not_active Expired - Lifetime
- 2001-09-17 US US09/954,304 patent/US6770620B2/en not_active Expired - Fee Related
- 2001-09-18 AT AT01967517T patent/ATE466592T1/de active
- 2001-09-18 PT PT01967517T patent/PT1414486E/pt unknown
- 2001-09-18 DE DE60142084T patent/DE60142084D1/de not_active Expired - Lifetime
- 2001-09-18 AU AU2001287892A patent/AU2001287892A1/en not_active Abandoned
- 2001-09-18 JP JP2002528284A patent/JP5189723B2/ja not_active Expired - Fee Related
- 2001-09-18 WO PCT/GB2001/004178 patent/WO2002024214A2/en active Application Filing
- 2001-09-18 ES ES01967517T patent/ES2345874T3/es not_active Expired - Lifetime
- 2001-09-18 EP EP01967517A patent/EP1414486B1/en not_active Expired - Lifetime
- 2001-09-18 DK DK01967517.2T patent/DK1414486T3/da active
2003
- 2003-03-18 US US10/391,460 patent/US6943151B2/en not_active Expired - Fee Related
2008
- 2008-08-13 CY CY20081100866T patent/CY1108263T1/el unknown
2010
- 2010-07-30 CY CY20101100721T patent/CY1110721T1/el unknown

Also Published As

Publication number	Publication date
JP5161412B2 (ja)	2013-03-13
JP5189723B2 (ja)	2013-04-24
PT1414486E (pt)	2010-07-21
WO2002024214A3 (en)	2004-02-19
AU2001287892A1 (en)	2002-04-02
AU2002213925A1 (en)	2002-03-26
CY1110721T1 (el)	2015-06-10
DE60134251D1 (de)	2008-07-10
ES2345874T3 (es)	2010-10-05
EP1326630A2 (en)	2003-07-16
EP1414486A2 (en)	2004-05-06
ATE466592T1 (de)	2010-05-15
CY1108263T1 (el)	2014-02-12
US20040082507A1 (en)	2004-04-29
ES2310192T3 (es)	2009-01-01
EP1326630B1 (en)	2008-05-28
DK1414486T3 (da)	2010-08-30
US20020037836A1 (en)	2002-03-28
WO2002024214A2 (en)	2002-03-28
US6943151B2 (en)	2005-09-13
DK1326630T3 (da)	2008-09-15
EP1970072A1 (en)	2008-09-17
JP2004508410A (ja)	2004-03-18
ATE396738T1 (de)	2008-06-15
US6770620B2 (en)	2004-08-03
WO2002022151A2 (en)	2002-03-21
WO2002022151A3 (en)	2003-03-13
JP2004524268A (ja)	2004-08-12
DE60142084D1 (de)	2010-06-17
EP1414486B1 (en)	2010-05-05

Publication	Publication Date	Title
PT1326630E (pt)	2008-09-02	Utilização de péptidos glp-2
HK1046845A1 (en)	2003-01-30	Vibrator for lower limbs, and chair type vibrator using the vibrator.
MXPA03003870A (es)	2004-08-12	Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes.
TWI315741B (en)	2009-10-11	A-isomaltosyltransferase, process for producing the same and use thereof
EA200300026A1 (ru)	2003-04-24	Аналоги глюкагоноподобного пептида-1
WO2002038052A3 (en)	2002-10-31	Steerable loop structure
CA98023S (en)	2002-09-30	Bottle
CA98021S (en)	2002-09-30	Bottle
MXPA02010604A (es)	2003-09-25	Barra para limpieza personal y proceso de preparacion.
CA99345S (en)	2002-10-30	Container
ZA200207650B (en)	2004-03-23	Absorbent structure and absorbent articles containing the absorbent structure.
MXPA03004932A (es)	2003-09-10	2-anilino-bencimidazoles sustituidos y su uso como inhibidores de nhe.
MXPA03010684A (es)	2005-11-04	Peptidos y el uso de los mismos para oscurecer la piel.
HK1039000A1 (en)	2002-04-04	Diffusion code generator, cdma communication apparatus using the same, and diffusion code generatingmethod used therefor
AU2003251529A8 (en)	2004-02-09	Planetarium and point light source for the use in same
MXPA03004613A (es)	2003-09-04	Compuestos de superabsorbente con alargamiento.
ZA200400313B (en)	2004-11-01	Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine.
IL161472A0 (en)	2004-09-27	In vitro micro-organs, and uses related thereto
ZA99535B (en)	2000-01-26	Oxygen generating device.
MXPA03001826A (es)	2003-06-04	Derivados de arilpiperazina.
GB2321244B (en)	2000-11-22	Vitamin D3 analogues,process for preparing them,and their use as antiproliferative and antitumour agents
IL156162A0 (en)	2003-12-23	Coniosetin and derivatives thereof, method for producing the same and use thereof.
IL145279A0 (en)	2002-06-30	Antibodies against caspase-8, their preparation and use
ZA200500219B (en)	2005-10-27	Modified bryodin 1 with reduced immunogenicity.
HK1041689A1 (en)	2002-07-19	((Aminoiminomethyl)amino) alkanecarboxamides and their applications in therapy.